PB-1002 is under clinical development by PendreaBio and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PB-1002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PB-1002 is under development for the treatment of hormone resistant prostate cancer, liver cancer, and pancreatic cancer. The drug candidate comprises synthetic, PEGylated nano-liposomal formulation of C6-ceramide. It acts by targeting protein phosphatase 2A.
PendreaBio formerly Keystone Nano, is a healthcare service provider that manufactures and markets nanoscale products to chemicals and pharmaceuticals companies. The center offers nanoparticle surfaces with passive and active targeting strategies. Its products are used for the treatment of solid-tumor and non-solid-tumor cancers, chemical research, diagnostic imaging and biological investigations, among others. PendreaBio’s NanoJacket and NanoLiposomes technologies supports to improve the delivery of chemicals and pharmaceuticals. The center also caters to medical, scientific and industrial sectors. It partners with pharmaceutical, biotechnology companies and cancer institutions, among others. PendreaBio is headquartered in State College, Pennsylvania, the US.
For a complete picture of PB-1002’s drug-specific PTSR and LoA scores, buy the report here.